According to NICE guidance (NG28), GLP-1 receptor agonists like Ozempic are typically considered when triple therapy is ineffective, not tolerated or contraindicated, with specific BMI and clinical criteria
Experienced vision loss diagnosed as NAION after using the drug
There are also new formulations that act on other receptors in addition to GLP-1 receptors to significantly increase the medication's effectiveness , in some cases doubling the weight reduction patients experience
Safety depends on: The specific peptide Product quality Proper dosing Medical oversight Individual health status Patients should avoid: Unregulated online peptide suppliers Self-injecting without guidance Social media biohacking advice Non-medical aesthetic recommendations A personalized medical consultation is the safest way to explore whether peptide therapy may align with your goals
This is about cellular health, not just lab results
As of early 2026, no peer-reviewed human clinical trials for BPC-157 have been published